Company: SHPH
Filing Date: 2025-03-13
Form Type: 424B3
Source: 0001493152-25-010109
Chunk: 49

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-13
Form: 424B3
Chunk 49
---
 year
from the date of issuance (the “Term”), accrues interest at the rate of 14.5% per annum, and is convertible at a 110%
premium at any time beginning three months after the date of issuance. The Company has the option to prepay the convertible notes at
any time, upon 10 days written notice, for 107% of total outstanding balance (the “Optional Prepayment Right”). Any
outstanding principal will be paid in conversion of shares of common stock at the end of the Term, subject to the Company’s
exercise of the Optional Prepayment Right; any accrued interest will be repaid quarterly in cash. The conversion price of the
convertible notes will be the lower of a 15% discount to (i) $1.12072 per share or (ii) the price of any offering entered into by
the Company during the Term of the convertible notes, including the Company’s planned follow-on offering. The warrants are
immediately exercisable after issuance and will remain exercisable for a period of five years from the date of issuance. The
exercise price is subject to adjustment for any stock split, stock dividend, stock combination, recapitalization or similar event. As of December 31, 2024, there was outstanding principal and interest balances for the related party note of $250,000 and $7,955, respectively. Under the fair value option, the senior convertible note is $206,085 as of December 31, 2024.

On March 5, 2025, the
Company entered into a loan agreement with our Chief Executive Officer, Dr. Anatoly Dritschilo, pursuant to which Dr. Dritschilo loaned
the Company of $75,000 (principal), bearing interest at the rate of 18% per annum and which is repayable with accrued interest in one
month.

Review, Approval and Ratification of Related Party Transactions

All related party transactions are subject to the review, approval, or ratification of our board of directors or an appropriate committee thereof.

<div align='center'>CAPITALIZATION</div>

The following table sets forth our cash and cash equivalents and capitalization as of December 31, 2024:

| ● | on                                                                                                                                        
 an actual basis;                                                                                                                          |
| ● | on                                                                                                                                        
 a pro forma basis to reflect (i) a $2,000,000 Revolving Loan Agreement entered into on February 28, 2025 under which no loan amounts